Biosergen AB (OSTO:BIOSGN) ROCE % : -231.20% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biosergen AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -231.20%.

Biosergen AB ROCE % Historical Data

The historical data trend for Biosergen AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB ROCE % Chart

Biosergen AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-732.23

-158.02

-217.01

Biosergen AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial									-99.41	-239.87	-362.86	-535.28	-231.20

Biosergen AB ROCE % Calculation

Biosergen AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-27.028	/	( ( (33.79 - 10.997)	+	(7.201 - 5.085) )	/ 2 )
	=	-27.028	/	( (22.793	+	2.116)	/ 2 )
	=	-27.028	/	12.4545
	=	-217.01 %

Biosergen AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-27.192	/	( ( (7.201 - 5.085)	+	(25.487 - 4.081) )	/ 2 )
	=	-27.192	/	( ( 2.116	+	21.406 )	/ 2 )
	=	-27.192	/	11.761
	=	-231.20 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Biosergen AB (OSTO:BIOSGN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biosergen AB ROCE % Related Terms

Thank you for viewing the detailed overview of Biosergen AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosergen AB (OSTO:BIOSGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (OSTO:BIOSGN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Fogdevreten 2, Solna, SWE, 17165

Website

https://www.biosergen.net

Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB (OSTO:BIOSGN) Headlines

No Headlines